The NICE reappraisal of biologics in 2005: what rheumatologists need to know

被引：11

作者：

Bansback, NJ

Young, A

Brennan, A ^{[1
]}

机构：

[1] Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England

[2] St Albans Hosp, St Albans AL3 5PN, England

来源：

RHEUMATOLOGY | 2005年 / 44卷 / 01期

关键词：

Osteoarthritis; Synovitis; Angiogenesis; Innervation; Osteophyte; Macrophage; Chondrocalcinosis;

D O I：

10.1093/rheumatology/keh364

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 4

页数：2

共 10 条

[1]

[Anonymous], 2004, GUID METH TECHN APPR

[2]

Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1

[3] Re:: Wolfe et al.: Do rhematology cost-effectiveness analyses make sense? [J].

Brennan, A ;

Bansback, N .

RHEUMATOLOGY, 2004, 43 (05) :677-678

[4] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK [J].

Brennan, A ;

Bansback, N ;

Reynolds, A ;

Conway, P .

RHEUMATOLOGY, 2004, 43 (01) :62-72

[5]

*BRIT SOC RHEUM WO, 2001, GUID PRESCR TNF ALPH

[6]

Clark W, 2004, HEALTH TECHNOL ASSES, V8, P1

[7] Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years [J].

James, D ;

Young, A ;

Kulinskaya, E ;

Knight, E ;

Thompson, W ;

Ollier, W ;

Dixey, J .

RHEUMATOLOGY, 2004, 43 (03) :369-376

[8]

*NAT I CLIN EXC, 2003, TECHNOLOGY APPRAISAL, V72

[9]

Watson K, 2004, RHEUMATOLOGY, V43, P1

[10] Do rheumatology cost-effectiveness analyses make sense? [J].

Wolfe, F ;

Michaud, K ;

Pincus, T .

RHEUMATOLOGY, 2004, 43 (01) :4-6

← 1 →